{"original": "In relation to COVID-19, Friman et al. investigated the off-target effects of the broad-spectrum antiviral Remdesivir, one of the first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift assay, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "sampled": "In relation to COVID-19, Friman et team. investigated the off-target effects of the broad-spectrum antiviral Remdesivir, one of the first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal redirection operation, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "replacement_keys": [68, 33, 2, 67, 83, 11], "original_crit": -1.2507908344268799, "sampled_crit": -1.5326789617538452, "original_llm_likelihood": 0.49, "sampled_llm_likelihood": 0.4897959183673469}